SAN DIEGO, Nov. 29, 2016 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today
announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate
presentation at the LD Micro Main Event in Los Angeles, CA. Details of Dr. Lian's
presentation are below:
•
|
Viking
Therapeutics Presentation at the LD Micro Main Event
|
|
Time/Date:
|
Tuesday, December
6 at 1:30pm PT
|
|
Location:
|
Luxe Sunset Hotel,
Los Angeles, CA
|
|
Track:
|
4
|
To access the live webcast of Viking's presentation, please
visit "Webcasts & Presentations" within the News & Events
section of Viking's Investors page at www.vikingtherapeutics.com.
Additionally, a replay of the webcasts will be available on the
Viking website following the conference.
About Viking Therapeutics, Inc.
Viking
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
focused on the development of novel, first-in-class or
best-in-class therapies for metabolic and endocrine
disorders. The company's research and development activities
leverage its expertise in metabolism to develop innovative
therapeutics designed to improve patients' lives. Viking has
exclusive worldwide rights to a portfolio of five therapeutic
programs in clinical trials or preclinical studies, which are based
on small molecules licensed from Ligand Pharmaceuticals
Incorporated. The company's clinical programs include VK5211,
an orally available, non-steroidal selective androgen receptor
modulator, or SARM, in Phase 2 development for the treatment and
prevention of lean body mass loss in patients who have undergone
hip fracture surgery, VK2809, a small molecule thyroid beta agonist
in Phase 2 development for hypercholesterolemia and fatty liver
disease, and VK0612, a first-in-class, orally available drug
candidate in Phase 2 development for type 2 diabetes. Viking
is also developing novel and selective agonists of the thyroid beta
receptor for adrenoleukodystrophy, as well as two earlier-stage
programs targeting metabolic diseases and anemia.
Follow Viking on Twitter @Viking_VKTX.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-the-ld-micro-main-event-300369205.html
SOURCE Viking Therapeutics, Inc.